Monitoring intravenous immunoglobulin dosing regimens in chronic inflammatory demyelinating polyneuropathy: Search for a biomarker

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 8, 2013, Pages 830-

  Wakerley, Benjamin R ^a   Yuki, Nobuhiro ^a  

^a Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; COMPLEMENT ACTIVATION; DISEASE MARKER; DRUG DOSE REGIMEN; DRUG MONITORING; EDITORIAL; GUILLAIN BARRE SYNDROME; HUMAN; IN VITRO STUDY; MOTOR NEUROPATHY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STEADY STATE; TREATMENT OUTCOME;

EID: 84879943172     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-304826     Document Type: Editorial

References (3)

1. Kuitwaard K, van Doorn PA, Vermeulen M, et al. Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2013;84:859-61.
2. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012;366:2294-304.
3. Yuki N, Watanabe H, Nakajima T, et al. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2011;82:87-91.